Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration.
D-mannose is an essential monosaccharide constituent of glycoproteins and glycolipids. However, it is unknown how plasma mannose is supplied. The aim of this study was to explore the source of plasma mannose. Oral administration of glucose resulted in a significant decrease of plasma mannose concentration after 20 min in fasted normal rats. However, in fasted type 2 diabetes model rats, plasma mannose concentrations that were higher compared with normal rats did not change after the administration of glucose. When insulin was administered intravenously to fed rats, it took longer for plasma mannose concentrations to decrease significantly in diabetic rats than in normal rats (20 and 5 min, respectively). Intravenous administration of epinephrine to fed normal rats increased the plasma mannose concentration, but this effect was negated by fasting or by administration of a glycogen phosphorylase inhibitor. Epinephrine increased mannose output from the perfused liver of fed rats, but this effect was negated in the presence of a glucose-6-phosphatase inhibitor. Epinephrine also increased the hepatic levels of hexose 6-phosphates, including mannose 6-phosphate. When either lactate alone or lactate plus alanine were administered as gluconeogenic substrates to fasted rats, the concentration of plasma mannose did not increase. When lactate was used to perfuse the liver of fasted rats, a decrease, rather than an increase, in mannose output was observed. These findings indicate that hepatic glycogen is a source of plasma mannose.
Taguchi
T
T
Dept. of Pathobiochemistry, Faculty of Pharmacy, Meijo Univ., 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan.
Yamashita
E
E
Mizutani
T
T
Nakajima
H
H
Yabuuchi
M
M
Asano
N
N
Miwa
I
I
D000284:Administration, Oral; D000409:Alanine / Q000494:pharmacology; D000818:Animals; D001089:Arabinose; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002726:Chlorogenic Acid / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism; D004195:Disease Models, Animal; D004837:Epinephrine / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D005952:Glucose-6-Phosphatase / Q000037:antagonists & inhibitors; D006003:Glycogen / Q000378:metabolism*; D024981:Glycogen Phosphorylase / Q000037:antagonists & inhibitors; D006600:Hexosephosphates / Q000032:analysis / Q000378:metabolism; D050113:Imino Furanoses; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D019344:Lactic Acid / Q000494:pharmacology; D008099:Liver / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008358:Mannose / Q000097:blood* / Q000378:metabolism; D008954:Models, Biological; D051381:Rats; D011919:Rats, Inbred Strains; D017208:Rats, Wistar; D013402:Sugar Alcohols / Q000494:pharmacology
D001786:Blood Glucose; D006600:Hexosephosphates; D050113:Imino Furanoses; D007328:Insulin; D013402:Sugar Alcohols; C058137:1,4-dideoxy-1,4-iminoarabinitol; D002726:Chlorogenic Acid; D019344:Lactic Acid; D006003:Glycogen; D001089:Arabinose; D024981:Glycogen Phosphorylase; D005952:Glucose-6-Phosphatase; D005947:Glucose; D000409:Alanine; D008358:Mannose; D004837:Epinephrine